Coronavirus Disease COVID 19 News and Research

Latest Coronavirus Disease COVID 19 News and Research

In vitro effect of several antiviral drugs against various SARS-CoV-2 variants of concern

An independent study confirms that current and prospective antiviral treatments are effective in inhibiting severe infection from SARS-CoV-2.

4 Jan 2022

Study finds pan-sarbecovirus nanobodies can enhance development of super-immunity

A new study found that applying pan-sarbecovirus nanobodies shows a strong affinity toward all sarbecovirus clades and neutralized SARS-CoV-2 receptor binding domains

4 Jan 2022

Why an HBCU med school decided to put CARES Act money into students’ pockets

Just before students at Meharry Medical College went home for Thanksgiving, Dr. James Hildreth, the school's president, emailed them a video message that he acknowledged seemed hard to believe. Or at least they had to give it a second listen.

4 Jan 2022

Siemens Healthineers Announces FDA Emergency Use Authorization for CLINITEST® Rapid COVID-19 Antigen Self-Test

The CLINITEST Rapid COVID-19 Antigen Self-Test has received FDA EUA for unsupervised self-testing for the SARS-CoV-2 virus by individuals age 14 and older (or adult-collected samples from individuals ages 2-13).

From Siemens Healthineers 4 Jan 2022

Sino Biological Deposits Recombinant Omicron Proteins and Antibodies to BEI Resources

Sino Biological, Inc. (SZSE: 301047) has recently deposited reagents for the Omicron variant, including recombinant proteins to Spike and Nucleocapsid, and antibody products to BEI Resources, a central repository for reagents to support infectious disease research.

From Sino Biological Inc. 4 Jan 2022

SARS-CoV-2 spike T cell responses from vaccines or infection remain robust against Omicron

In a new study, a team of researchers from multi-national institutions discovered that 70-80% of CD4 and CD8 T cell responses to spike were consistent across research groups. Moreover, although having far more mutations, the magnitude of Omicron cross-reactive T cells was comparable to that of the Beta and Delta variants.

3 Jan 2022

Very high rates of asymptomatic infection with Omicron compared to prior SARS-CoV-2 variants

The advent of the B.1.1.529 (Omicron) severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) variant, detected initially in Botswana and South Africa and now found in over 135 countries as of January 3, 2022, has sparked fears of a new global wave of infections and hospitalizations

3 Jan 2022

SARS-CoV-2 differs from other betacoronaviruses in a key IRE1α/XBP1 pathway

SARS-CoV-2 differs from other viruses in the beta coronavirus family in the activation of a key pathway associated with endoplasmic reticulum stress.

3 Jan 2022

Production of molecular probes of spike and subdomains for all SARS-CoV-2 variants

Researchers designed molecular probes of diverse SARS-CoV-2 variants and evaluated their antibody binding specificity.

3 Jan 2022

The impact of natural selection on sequence diversity in SARS-CoV-2

Recent genomic analysis demonstrates that the SARS-CoV-2 genome is under two distinct selective forces.

3 Jan 2022

Modeling shows SARS-CoV-2 Omicron will place a severe burden on UK's health services

Researchers use data and a mathematical model to determine the impact of the SARS-CoV-2 Omicron variant on future risk of infection.

3 Jan 2022

CDC report shows COVID vaccines safe for children, serious side effects rare

Researchers determine the characteristics and clinical outcomes of COVID-19 in children and adolescents 18 years or younger.

3 Jan 2022

Omicron spike-specific binding antibodies attenuate disease, despite increasing transmission

Researchers investigate the capacity of vaccine-induced antibodies to generate Fc-effector activity against the SARS-CoV-2 Omicron variant.

3 Jan 2022

T-cell responses to SARS-CoV-2 Omicron variant confer protection to vaccinated individuals

Researchers ascertain whether the SARS-CoV-2 Omicron variant evades cellular immunity.

3 Jan 2022

Genomic sequencing supports a long-term infection as source of SARS-CoV-2 Omicron

Researchers study the nucleotide sequences of the newly emerged SARS-CoV-2 Omicron variant with other nucleotide sequences in the GISAID database.

3 Jan 2022

SARS-CoV-2 Omicron variant highly resistant to vaccine-elicited and therapeutic antibodies

Researchers analyzed convalescent sera and sera from immunized individuals to demonstrate the evasion of antibodies by the SARS-CoV-2 Omicron variant.

3 Jan 2022

COVID-19 tests with the new assay may be just as reliable as laboratory-based molecular tests

Researchers at the University of Illinois Chicago have designed a high-quality assay that can be used in at-home tests for rapid COVID-19 screening.

3 Jan 2022

Humanized antibody shows strong neutralization ability against SARS-CoV-2 Delta variant

Researchers combine SARS-CoV-2 spike vaccination with single-cell B-cell receptor sequencing technology to discover neutralizing antibody candidates.

3 Jan 2022

Minimal nAb titers against Omicron in the elderly after 3rd dose

Researchers measured titers of cross-protective neutralizing antibodies against SARS-CoV-2 after they had received a third booster dose.

3 Jan 2022

SARS-CoV-2 Omicron study on hamsters, shows virus results in a less severe disease

Researchers investigate the ability of immunity acquired from SARS-CoV-2 wild-type infection to protect against the Omicron variant in Syrian hamster models.

3 Jan 2022

Coronavirus Disease COVID 19 News and Research

Latest Coronavirus Disease COVID 19 News and Research

In vitro effect of several antiviral drugs against various SARS-CoV-2 variants of concern

Study finds pan-sarbecovirus nanobodies can enhance development of super-immunity

Why an HBCU med school decided to put CARES Act money into students’ pockets

Siemens Healthineers Announces FDA Emergency Use Authorization for CLINITEST® Rapid COVID-19 Antigen Self-Test

Sino Biological Deposits Recombinant Omicron Proteins and Antibodies to BEI Resources

SARS-CoV-2 spike T cell responses from vaccines or infection remain robust against Omicron

Very high rates of asymptomatic infection with Omicron compared to prior SARS-CoV-2 variants

SARS-CoV-2 differs from other betacoronaviruses in a key IRE1α/XBP1 pathway

Production of molecular probes of spike and subdomains for all SARS-CoV-2 variants

The impact of natural selection on sequence diversity in SARS-CoV-2

Modeling shows SARS-CoV-2 Omicron will place a severe burden on UK's health services

CDC report shows COVID vaccines safe for children, serious side effects rare

Omicron spike-specific binding antibodies attenuate disease, despite increasing transmission

T-cell responses to SARS-CoV-2 Omicron variant confer protection to vaccinated individuals

Genomic sequencing supports a long-term infection as source of SARS-CoV-2 Omicron

SARS-CoV-2 Omicron variant highly resistant to vaccine-elicited and therapeutic antibodies

COVID-19 tests with the new assay may be just as reliable as laboratory-based molecular tests

Humanized antibody shows strong neutralization ability against SARS-CoV-2 Delta variant

Minimal nAb titers against Omicron in the elderly after 3rd dose

SARS-CoV-2 Omicron study on hamsters, shows virus results in a less severe disease

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Coronavirus Disease COVID 19 News and Research

Latest Coronavirus Disease COVID 19 News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in